Monument Capital Management Trims Stock Holdings in Pfizer Inc. (NYSE:PFE)

Monument Capital Management lowered its holdings in Pfizer Inc. (NYSE:PFE) by 27.2% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 8,497 shares of the biopharmaceutical company’s stock after selling 3,180 shares during the period. Monument Capital Management’s holdings in Pfizer were worth $245,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Mengis Capital Management Inc. boosted its holdings in Pfizer by 0.9% in the fourth quarter. Mengis Capital Management Inc. now owns 63,650 shares of the biopharmaceutical company’s stock valued at $1,833,000 after purchasing an additional 550 shares during the last quarter. GUNN & Co INVESTMENT MANAGEMENT INC. acquired a new stake in Pfizer during the fourth quarter valued at approximately $2,601,000. Capital Investment Advisory Services LLC raised its stake in Pfizer by 12.5% during the fourth quarter. Capital Investment Advisory Services LLC now owns 98,200 shares of the biopharmaceutical company’s stock valued at $2,827,000 after buying an additional 10,931 shares in the last quarter. OLD National Bancorp IN raised its stake in Pfizer by 12.0% during the fourth quarter. OLD National Bancorp IN now owns 225,102 shares of the biopharmaceutical company’s stock valued at $6,481,000 after buying an additional 24,165 shares in the last quarter. Finally, Brendel Financial Advisors LLC acquired a new stake in Pfizer during the fourth quarter valued at approximately $2,854,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Up 1.0 %

PFE opened at $26.26 on Tuesday. Pfizer Inc. has a 12 month low of $25.23 and a 12 month high of $40.37. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. The stock has a market cap of $148.70 billion, a P/E ratio of 72.94, a P/E/G ratio of 1.17 and a beta of 0.61. The stock’s 50 day moving average price is $27.08 and its 200 day moving average price is $28.56.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 EPS for the quarter, beating the consensus estimate of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The firm had revenue of $14.25 billion for the quarter, compared to analysts’ expectations of $14.37 billion. During the same period last year, the firm earned $1.14 EPS. The firm’s revenue was down 41.3% compared to the same quarter last year. As a group, research analysts predict that Pfizer Inc. will post 2.24 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on PFE. Guggenheim began coverage on Pfizer in a research note on Friday, February 23rd. They set a “buy” rating and a $36.00 price objective on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a research note on Monday, April 15th. Argus cut Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Finally, TD Cowen cut Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective on the stock. in a research note on Thursday, January 4th. Eleven analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, Pfizer presently has a consensus rating of “Hold” and an average price target of $36.33.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.